Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.74 |
| ▸ | PPARG | P37231 | 7/20 | 0.74 |
| ▸ | PPARD | Q03181 | 7/20 | 0.74 |
| ▸ | PPARA | Q07869 | 7/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 5/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.74 |
| ▸ | FABP4 | P15090 | 3/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | TLR2 | O60603 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.74 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743610 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL14166454 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL11477071 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL16539035 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL7201642 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL8865709 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL15593804 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL7749100 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL2229369 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL9106361 | 1.00 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060014-A1 | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents | US ARMY, SECRETARY OF THE ARMY | 2011-03-10 | — | — | US | claimed |
| EP-1315831-B8 | STEAROYL-COA DESATURASE TO IDENTIFY TRIGLYCERIDE REDUCING THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2010-09-01 | — | — | EP | claimed |
| US-20050250160-A1 | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents | HAYDEN MICHAEL R | 2005-11-10 | — | — | US | claimed |
| JP-2003533978-A | — | — | 2003-11-18 | — | — | JP | claimed |
| WO-2003075925-A1 | METHODS FOR REDUCING BODY FAT AND INCREASING A LEAN BODY MASS BY REDUCING STEAROYL-COA DESATURASE 1 ACTIVITY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030157552-A1 | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents | US ARMY, SECRETARY OF THE ARMY | 2003-08-21 | — | — | US | claimed |
| EP-1315831-A2 | STEAROYL-COA DESATURASE TO IDENTIFY TRIGLYCERIDE REDUCING THERAPEUTIC AGENTS | Xenon Genetics Inc. (CA) | 2003-06-04 | — | — | EP | claimed |
| US-20030064950-A1 | Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-04-03 | — | — | US | claimed |
| WO-2001062954-A2 | STEAROYL-COA DESATURASE TO IDENTIFY TRIGLYCERIDE REDUCING THERAPEUTIC AGENTS | XENON GENETICS, INC. (CA) | 2001-08-30 | — | — | WO | claimed |
| US-20180153830-A1 | SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-06-07 | — | — | US | disclosed |
| US-20170027890-A1 | SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-02-02 | — | — | US | disclosed |
| US-9456998-B2 | Selective inhibitors of undifferentiated cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-10-04 | — | — | US | disclosed |
| EP-3042895-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2016-07-13 | — | — | EP | disclosed |
| EP-2054408-B1 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-20030157552-A1 | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents | US ARMY, SECRETARY OF THE ARMY | 2003-08-21 | — | — | US | disclosed |
| EP-1315831-A2 | STEAROYL-COA DESATURASE TO IDENTIFY TRIGLYCERIDE REDUCING THERAPEUTIC AGENTS | Xenon Genetics Inc. (CA) | 2003-06-04 | — | — | EP | disclosed |
| US-20030064950-A1 | Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-04-03 | — | — | US | disclosed |
| WO-2001062954-A2 | STEAROYL-COA DESATURASE TO IDENTIFY TRIGLYCERIDE REDUCING THERAPEUTIC AGENTS | XENON GENETICS, INC. (CA) | 2001-08-30 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153830-A1 | SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS | MCL1, MKI67, SCD | GPR84 2944/4885PPARG 1844/4885PPARD 2642/4885 |
| US-20170027890-A1 | SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS | MCL1, MKI67, SCD | GPR84 2944/4885PPARG 1844/4885PPARD 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.